Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

被引:31
|
作者
Brown, T. [1 ]
Pilkington, G. [1 ]
Boland, A. [1 ]
Oyee, J. [1 ]
Smith, C. Tudur [2 ]
Dundar, Y. [1 ]
Richards, E. [3 ]
Yang, R. [4 ]
Dickson, R. [1 ]
机构
[1] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool L69 3BX, Merseyside, England
[2] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England
[3] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
[4] Peking Univ, Inst Populat Res, Beijing 100871, Peoples R China
关键词
QUALITY-OF-LIFE; RANDOMIZED PHASE-II; LEUKEMIA GROUP-B; STAGE-III; CONCOMITANT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; WEEKLY PACLITAXEL; TRIAL; CHEMOTHERAPY; CISPLATIN;
D O I
10.3310/hta17060
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Lung cancer is the most common cancer in the world and the second most common cancer diagnosed in the UK after breast cancer. In 2008, there were 40,806 new cases of lung cancer diagnosed in the UK, with 32,546 in England and 2403 in Wales.(1) Lung cancer is rarely diagnosed in people <40 years of age, and 86% of cases occur in people >60 years.(1) Table 1 provides an overview of lung cancer statistics in the UK. The European age-standardised incidence rate of lung cancer in 2008 was 45.6 per 100,000 population in England and 52.2 per 100,000 population in Wales.(1) The UK incidence rate in men is similar to incidence rates in most of Western Europe and is lower than incidence rates in most of Eastern Europe. 1 The UK incidence rate in women is one of the highest rates in the European Union.(1) There is an increased incidence of lung cancer in individuals from the lowest socioeconomic strata.(2) In 2008, around 65,000 individuals were living with lung cancer in the UK; 1 the majority of these individuals were men.(1)
引用
收藏
页码:1 / +
页数:101
相关论文
共 50 条
  • [1] A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
    Pilkington, Gerlinde
    Boland, Angela
    Brown, Tamara
    Oyee, James
    Bagust, Adrian
    Dickson, Rumona
    THORAX, 2015, 70 (04) : 359 - 367
  • [2] First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis
    Hess, Lisa M.
    DeLozier, Amy M.
    Natanegara, Fanni
    Wang, Xiaofei
    Soldatenkova, Victoria
    Brnabic, Alan
    Able, Stephen L.
    Brown, Jacqueline
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6677 - +
  • [3] Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review
    Bearz, Alessandra
    Berretta, Massimiliano
    Tirelli, Umberto
    CURRENT CANCER DRUG TARGETS, 2018, 18 (05) : 405 - 409
  • [4] First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
    Goffin, John
    Lacchetti, Christina
    Ellis, Peter M.
    Ung, Yee C.
    Evans, William K.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 260 - 274
  • [5] Chemoradiation for locally advanced non-small cell lung cancer
    Girard, N.
    Mornex, F.
    CANCER RADIOTHERAPIE, 2007, 11 (1-2): : 67 - 76
  • [6] Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer
    Garcia-Fumero, Ricardo
    Fernandez-Lopez, Cristina
    Calleja-Hernandez, Miguel angel
    Exposito-Ruiz, Manuela
    Espin, Jaime
    Exposito-Hernandez, Jose
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (10): : 433 - 438
  • [7] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [8] Is Concurrent Chemoradiation the Standard of Care for Locally Advanced Non-small Cell Lung Cancer? A Review of Guidelines and Evidence
    O'Rourke, N.
    Macbeth, F.
    CLINICAL ONCOLOGY, 2010, 22 (05) : 347 - 355
  • [9] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Petrelli, Fabio
    Scuri, Stefania
    Binh Thanh Nguyen
    Grappasonni, Iolanda
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (05) : 763 - 777
  • [10] Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
    Chu, Q
    Vincent, M
    Logan, D
    Mackay, JA
    Evans, WK
    LUNG CANCER, 2005, 50 (03) : 355 - 374